AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00938184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 12.5 milligrams tablet
Description: Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
Study NCT00938184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 25 milligrams tablet
Description: Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
Study NCT00938184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 50 milligrams tablet
Description: Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
Study NCT00979901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 10 mg montelukast tablet given once daily at bedtime for 2 weeks
Study NCT00979901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: loratadine
Description: 10 mg loratadine tablet given once daily at bedtime for 2 weeks
Study NCT00979901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet given once daily at bedtime for 2 weeks
Study NCT00979901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast/loratadine
Description: montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
Study NCT01702974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
Description: Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
Study NCT01702974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
Study NCT02228707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Participants receive BIIB061
Study NCT02228707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00778934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Health Gel
Description: Intimate Health Gel
Study NCT00555958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active, implantable, intra-abdominal vagal blocking medical device
Description: Intermittent, programmable, intra-abdominal vagal blocking
Study NCT02231112 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole breast RT on prone position
Study NCT01672385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring plus self-management support
Description: Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
Study NCT00382668 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg, once daily, for one day
Study NCT00382668 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 20 mg, once daily for one day
Study NCT00382668 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, once daily for one day
Study NCT01608711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-1C4D4
Description: Intravenous Infusion
Study NCT01608711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenous Infusion
Study NCT01731912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT01731912 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo standard EBRT
Study NCT01731912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02446977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B2 Streuli®
Description: 4ml IV
Study NCT02446977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Solution for injection
Description: 4ml IV
Study NCT00875186 — intervention group
Intervention type: OTHER
Intervention: aerobic endurance training
Description: participants exercises 2 times weekly for 1 hour (aerobic endurance training)
Study NCT00875186 — intervention group
Intervention type: OTHER
Intervention: aerobic endurance training
Description: participants exercised 1 time weekly for 1 hour (aerobic endurance training)
Study NCT03777358 — intervention group
Intervention type: DEVICE
Intervention: 3D-TVS
Description: The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
Study NCT00935181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory muscle stretching
Description: stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
Study NCT03010696 — intervention group
Intervention type: OTHER
Intervention: No interventions, questionnaire, collect specimen
Study NCT03972059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 1
Description: Phase 1 is the first 4 weeks of the 12-week training program.
Study NCT03972059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 2
Description: Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
Study NCT03972059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 3
Description: Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
Study NCT03816033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Catheter ablation treatment for the treatment of the studied arrhythmias
Study NCT03816033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Catheter ablation treatment for the treatment of the studied arrhythmias
Study NCT00346216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 100 to 200 mg twice daily, taken by mouth
Study NCT00346216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen 600 mg to 800 mg three times daily, taken by mouth
Study NCT00346216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: naproxen 375mg to 500 mg twice daily, taken by mouth
Study NCT02324946 — intervention group
Intervention type: OTHER
Intervention: Mass Screening
Description: Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
Study NCT03115359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Therapy
Description: The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
Study NCT03115359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
Study NCT00910689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol or nadolol
Description: Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
Study NCT00910689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo
Study NCT00910689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: Placebo
Study NCT00910689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Migraine Management (BMM)
Description: Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed
Study NCT00910689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimal Acute Therapy
Description: This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
Study NCT00910689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Acute Therapy
Description: This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
Study NCT03856060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04279132 — intervention group
Intervention type: BEHAVIORAL
Intervention: POSTOPERATIVE COGNITIVE DYSFUNCTION
Description: NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
Study NCT03856060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watch videos of doctor and patient interaction in different settings
Study NCT02792673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)
Study NCT02792673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)
Study NCT02792673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid
Study NCT03760029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visit frequency
Description: All subjects need to visit sites more frequently than in routine clinical practice.
Study NCT03392896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
Study NCT03392896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
Study NCT00473434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: 3mg or 6mg or 9mg or 12mg once daily for 52 weeks
Study NCT02792673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Labotect embryo transfer catheter
Study NCT02792673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labotect embryo transfer catheter
Study NCT04025346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsimax
Description: 1 capsule to be taken before breakfast.
Study NCT01285401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VigantOL oil plus interferon beta-1a (Rebif)
Description: VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
Study NCT01285401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus interferon beta-1a (Rebif)
Description: Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
Study NCT01285401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif®) alone
Description: Rebif® 44 mcg tiw, sub-cutaneously alone.
Study NCT03581942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: (MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
Study NCT03581942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: (MTD) Copanlisib 60 mg weekly (3w on/1w off)
Study NCT02384551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification
Study NCT02384551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification
Study NCT04218968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
Study NCT02370329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02370329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02370329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ropeginterferon Alfa-2B
Description: Given SC
Study NCT04025346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsimax
Description: 1 capsule to be taken before breakfast.
Study NCT04025346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro Crystalline Cellulose
Description: 1 capsule to be taken before breakfast.
Study NCT01874197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: B-TEVAR device
Description: Implantation of the Branched Thorcoabdominal aortic anerysm device
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I.
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
Study NCT02529852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
Study NCT03532542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casimersen
Description: Casimersen solution for IV infusion
Study NCT03532542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golodirsen
Description: Golodirsen solution for IV infusion
Study NCT03354013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AOA
Description: 100% ICSI-AOA will be performed.
Study NCT03354013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic screening
Description: Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
Study NCT03354013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Calcium pattern analysis
Description: Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
Study NCT01904188 — intervention group
Intervention type: DEVICE
Intervention: Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)
Description: The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
Study NCT03802578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAND EXERCISE
Study NCT00938158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide
Study NCT05043363 — intervention group
Intervention type: DEVICE
Intervention: LumenEye X1 digital rectoscope
Description: The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
Study NCT01968486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT standard fluence, ranibizumab
Description: In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
Study NCT01968486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT reduced fluence, ranibizumab
Description: In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.